FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | S IN BENEFICIAL | L OWNERSHIP |
|-----------|------------|-----------------|-------------|

| OMB APPROVAL | | | | | | | | |
|----------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average bu | rden | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | _ | | | | | | , | | | | | | | |
|---|---|--|--|-----------------|--|---|---------|-------------------------|--|------------------------|-----------------------|---|--|---|---|---|-----------|--|
| 1. Name and Address of Reporting Person* Buck Kristen K | | | | 2. II | 2. Issuer Name and Ticker or Trading Symbol LISATA THERAPEUTICS, INC. [LSTA] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Check Specify) | | | | | |
| (Last) (First) (Middle) C/O LISATA THERAPEUTICS, INC. 110 ALLEN ROAD, 2ND FLOOR | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/09/2023 | | | | | | | | X Officer (give title Other (specify below) EVP, R&D and CMO | | | | |
| (Street) BASKING RIDGE NJ 07920 | | | | 4. l | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | Lin | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (St | tate) | (Zip) | | | | | | | | | | | | | | | |
| | | Tab | le I - No | n-Deriv | vativ | e Se | curitie | s Ac | quired, | Dis | posed o | f, or Be | neficial | ly Owned | I | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) | | | | Execution Date, | | e, Transaction Dis | | 4. Securiti Disposed | rities Acquired (A) ed Of (D) (Instr. 3, 4 | | Benefici | es ally Following | Form (D) or | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Transac (Instr. 3 | on(s) | | | (Instr. 4) |
| Common Stock 01/09/2 | | | | 9/2023 | 2023 | | A | | 18,000 ⁽¹⁾ A | | \$0 | 38,482(2) | | | D | | | |
| Common Stock 01/09/ | | | | 9/2023 | 2023 | | | F | | 2,147 ⁽³⁾ D | | \$3 | 36, | 36,335(2) | | D | | |
| Common Stock 01/10/2 | | | | 0/2023 | /2023 | | F | | 512 ⁽³⁾ D | | \$3.19 | 95 35,823 ⁽⁴⁾ | | | D | | | |
| | | ٦ | Table II - | | | | | | | | osed of, convertil | | | Owned | | , | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deeme Execution if any (Month/Day | Date, | 4. Transa Code (8) | | n of | | 6. Date Exercisa Expiration Date (Month/Day/Year | | | Amount of Securities Underlying Derivative | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | Owners Form: Ily Direct (I or Indire (I) (Instr | Ownership | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | | Code | v | (A) | | Date Exercisab | | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Stock Options (Right to | \$3 | 01/09/2023 | | | A | | 9,000 | | 01/09/202 | 3 ⁽⁵⁾ | 01/09/2033 | Common Stock | 9,000 | \$0 | 9,000 |) | D | |

Explanation of Responses:

- 1. Represents 18,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
- 2. Includes 23,808 unvested restricted stock awards.
- 3. Shares withheld as payment of a tax liability on vesting of restricted stock.
- 4. Includes 22,733 unvested restricted stock awards.
- 5. One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.

Remarks:

James Nisco, Attorney-in-Fact for Kristen K. Buck

01/11/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.